Therapeutic Benefit of Larotrectinib vs Standard of Care in Locally Advanced or Metastatic Infantile Fibrosarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ESMO Open
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)
ESMO Open 2024 Apr 23;9(5)103006, D Orbach, M Carton, SK Khadir, M Feuilly, M Kurtinecz, C Vokuhl, E Koscielniak, G Pierron, L Lemelle, M Sparber-SauerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.